CD19 and juvenile dermatomyositis: 6) Pediatric ARDs applications: While CD19 CAR-T cells have shown promise in pediatric SLE and juvenile dermatomyositis (57), their efficacy in other childhood chronic inflammatory rheumatic diseases remains unexplored.